Top news of the week: 09.05.2022.
Healthcare
Clay Siegall, founding Seagen CEO, takes leave amid domestic violence accusation
The company's board is investigating the allegation, which Siegall, who has led Seattle's largest biotech for 24 years, denied. Chief Medical Officer Roger Dansey, a former Merck & Co. ...
Neuromuscular disease biotech PepGen prices IPO at $12, below the range
PepGen, a Phase 1 biotech developing oligonucleotide therapies for neuromuscular diseases, raised $108 million by offering 9 million shares at $12, below the range of $13 to $15.
Cancer Immunotherapy Developers in Asia Explore Diverse Approaches
Novel concepts include intra-cellular-antigen-binding antibodies, light-activated drugs, antiviral T cells, and PD-1-based DNA vaccines.
How to create a stand-out customer experience for cell and gene therapies
The end-to-end customer experience (CX) needed for a cell or gene therapy (CGT) to reach a patient is much different than that of a traditional biopharma product. A standout CX starts with ...
Biotech Co. Advances COVID-19 Vaccines Toward Approval Research Report
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.
Career Opportunities: Associate or Senior Editor: Reviews, Nature Biotechnology (42157)
Nature Research is a flagship portfolio of journals, products and services including Nature and the Nature-branded journals, dedicated to serving the scientific …